Verily and Samsung agreed to integrate Galaxy smartwatch data into Verily’s Pre platform to provide an end‑to‑end system for deploying wearables in clinical research, collecting passive physiological data, and analyzing results remotely. The partnership aims to streamline wearable deployment for pharma sponsors and CROs and standardize data ingestion from consumer devices. Separately, a Nature Health study introduced DocTr, an AI system that matches clinicians and sites to trials with 58% higher similarity to optimal recommendations than baseline methods. DocTr operates upstream in site selection—identifying investigators with practice patterns and enrollment histories that fit trial criteria—and is positioned as a complement to patient‑level matching tools. Together, these developments reflect growing investment in digital and AI tools to accelerate recruitment and decentralized trial designs.